Breaking News Instant updates and real-time market news.

JAZZ

Jazz Pharmaceuticals

$108.04

-2.94 (-2.65%)

16:06
11/28/16
11/28
16:06
11/28/16
16:06

Jazz Pharmaceuticals: Patient enrollment complete for Phase 3 study of JZP-110

Jazz Pharmaceuticals announced that patient enrollment has been completed in its Phase 3 study evaluating JZP-110 in excessive sleepiness associated with narcolepsy. "This is an important milestone in our JZP-110 Phase 3 program," said Karen Smith, M.D., Ph.D., global head of research and development and chief medical officer of Jazz Pharmaceuticals. "We expect to report the top-line results from our two Phase 3 studies evaluating ES in obstructive sleep apnea in the first quarter of 2017 and the top-line results from this Phase 3 narcolepsy study in the second quarter of 2017."

  • 29

    Nov

  • 03

    Dec

  • 14

    Dec

JAZZ Jazz Pharmaceuticals
$108.04

-2.94 (-2.65%)

10/05/16
BMOC
10/05/16
NO CHANGE
Target $195
BMOC
Outperform
Jazz Pharmaceuticals risk/reward favorable, says BMO Capital
BMO Capital analyst Gary Nachman said recent Jazz Pharmaceutical management meetings confirm his positive thesis and said risk/reward in shares is favorable at current levels. Nachman said management sounded very confident in the company's outlook and he remains optimistic that a favorable Xyrem settlement would lift a significant overhang on the stock and help unlock untapped value with the pipeline. The analyst reiterates his Outperform rating and $195 price target on shares.
10/28/16
LEER
10/28/16
NO CHANGE
Target $178
LEER
Outperform
Jazz Pharmaceuticals price target lowered to $178 from $202 at Leerink
Leerink analyst Jason Gerberry lowered his price target for Jazz Pharmaceuticals to $178 from $202 on valuation. However, the analyst continues to recommend investors buy Jazz Pharmaceuticals' shares given the "strong" 2017 catalyst outlook, including a likely continuation of Xyrem patent settlements, favorable Phase 3 data for JZP-110 for excessive daytime sleepiness and approval of Vyxeos for secondary Acute Myeloid Leukemia. Gerberry reiterates an Outperform rating on the shares.
11/09/16
UBSW
11/09/16
NO CHANGE
Target $168
UBSW
Buy
Jazz Pharmaceuticals well positioned for 2017, says UBS
UBS analyst Marc Goodman said he likes Jazz Pharmaceuticals' setup for 2017, noting its easier comps, the potential settlement of its Xyrem patent trial, data expected from its pipeline, and expectations for approval of its Vyxeos drug candidate. Goodman reiterated his Buy rating and $168 price target on Jazz Pharmaceuticals shares following the company's Q3 report.
11/09/16
LEER
11/09/16
NO CHANGE
Target $182
LEER
Outperform
Jazz Pharmaceuticals price target raised to $182 from $178 at Leerink
Leerink analyst Jason Gerberry raised his price target for Jazz Pharmaceuticals to $182 from $178 as he sees the 2017 setup as favorable with likely Xyrem legal patent settlements, abating investor concerns around governmental scrutiny over historical Xyrem price increases, JZP-110 Phase 3 data and a likely approval for Vyxeos in secondary Acute Myeloid Leukemia. The analyst reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

HAR

Harman

$109.79

0.125 (0.11%)

10:57
12/06/16
12/06
10:57
12/06/16
10:57
Hot Stocks
Breaking Hot Stocks news story on Harman »

JP Morgan lowers passive…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 10

    Jan

BWA

BorgWarner

$38.48

0.99 (2.64%)

10:56
12/06/16
12/06
10:56
12/06/16
10:56
Technical Analysis
BorgWarner moves higher, potential bullish pattern »

The shares are up over…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jan

EC

Ecopetrol

$8.74

0.14 (1.63%)

10:56
12/06/16
12/06
10:56
12/06/16
10:56
Recommendations
Ecopetrol analyst commentary  »

Ecopetrol added to the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOG

Alphabet

$762.52

12.02 (1.60%)

, GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

10:55
12/06/16
12/06
10:55
12/06/16
10:55
Hot Stocks
Google Wifi now available for purchase »

According to an email by…

GOOG

Alphabet

$762.52

12.02 (1.60%)

GOOGL

Alphabet Class A

$778.22

13.76 (1.80%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Jan

VLKAY

Volkswagen

$27.98

0.8 (2.94%)

10:55
12/06/16
12/06
10:55
12/06/16
10:55
Conference/Events
House Energy & Commerce Committee to hold a hearing »

The Oversight &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 05

    Jan

  • 10

    Jan

BOBE

Bob Evans

$46.77

1.05 (2.30%)

, JPM

JPMorgan

$82.99

-0.27 (-0.32%)

10:51
12/06/16
12/06
10:51
12/06/16
10:51
Hot Stocks
Bob Evans holder Sandell 'encouraged' by retention of financial advisor »

Sandell Asset Management,…

BOBE

Bob Evans

$46.77

1.05 (2.30%)

JPM

JPMorgan

$82.99

-0.27 (-0.32%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 06

    Dec

  • 06

    Dec

  • 09

    Jan

  • 13

    Jan

  • 28

    Feb

  • 14

    Jul

  • 12

    Oct

ETE

Energy Transfer Equity

$16.24

0.17 (1.06%)

10:50
12/06/16
12/06
10:50
12/06/16
10:50
Options
Notable call spreads in Energy Transfer Equity »

Notable call spreads in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$60.22

0.97 (1.64%)

, LNKD

LinkedIn

$195.41

0.16 (0.08%)

10:49
12/06/16
12/06
10:49
12/06/16
10:49
Hot Stocks
European Commission approves acquisition of LinkedIn by Microsoft »

The European Commission…

MSFT

Microsoft

$60.22

0.97 (1.64%)

LNKD

LinkedIn

$195.41

0.16 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BW

Babcock & Wilcox

$16.02

0.03 (0.19%)

10:47
12/06/16
12/06
10:47
12/06/16
10:47
Conference/Events
Babcock & Wilcox management to meet with William Blair »

Group luncheon with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

RIG

Transocean

$14.13

0.15 (1.07%)

10:47
12/06/16
12/06
10:47
12/06/16
10:47
Hot Stocks
Transocean announces approval of merger with Transocean Partners »

Transocean announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WERN

Werner

$27.90

0.2 (0.72%)

10:46
12/06/16
12/06
10:46
12/06/16
10:46
Conference/Events
Werner management to meet with Stephens »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SNN

Smith & Nephew

$28.77

0.27 (0.95%)

10:46
12/06/16
12/06
10:46
12/06/16
10:46
Conference/Events
Smith & Nephew management to meet with Jefferies »

Meeting to be held in the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

RP

RealPage

$28.80

0.25 (0.88%)

10:45
12/06/16
12/06
10:45
12/06/16
10:45
Conference/Events
RealPage management to meet with JMP Securities »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 13

    Dec

10:45
12/06/16
12/06
10:45
12/06/16
10:45
General news
The U.S. factory goods data slightly underperformed »

The U.S. factory goods…

BAC

Bank of America

$21.81

-0.03 (-0.14%)

10:44
12/06/16
12/06
10:44
12/06/16
10:44
Hot Stocks
Bank of America CEO: $53B cost-cutting target reflects 'environment we're in' »

Says "tremendous…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 13

    Jan

RP

RealPage

$28.80

0.25 (0.88%)

10:44
12/06/16
12/06
10:44
12/06/16
10:44
Conference/Events
RealPage management to meet with Stephens »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 13

    Dec

MMI

Marcus & Millichap

$27.72

-0.1 (-0.36%)

10:44
12/06/16
12/06
10:44
12/06/16
10:44
Conference/Events
Marcus & Millichap management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

IT

Gartner

$101.15

0.46 (0.46%)

10:43
12/06/16
12/06
10:43
12/06/16
10:43
Conference/Events
Gartner management to meet with William Blair »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

HIBB

Hibbett Sports

$42.55

2.1 (5.19%)

10:42
12/06/16
12/06
10:42
12/06/16
10:42
Conference/Events
Hibbett Sports management to meet with Canaccord »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

ISRG

Intuitive Surgical

$636.95

0.31 (0.05%)

10:42
12/06/16
12/06
10:42
12/06/16
10:42
Technical Analysis
Intuitive Surgical falls, levels to watch »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 07

    Dec

AOSL

Alpha & Omega

$20.51

0.43 (2.14%)

10:40
12/06/16
12/06
10:40
12/06/16
10:40
Conference/Events
Alpha & Omega management to meet with Drexel Hamilton »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SBUX

Starbucks

$57.50

0.29 (0.51%)

10:40
12/06/16
12/06
10:40
12/06/16
10:40
Options
Option action heats up in Starbuck's weeklys »

Option action heats up in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

AIRM

Air Methods

$32.70

0.15 (0.46%)

10:39
12/06/16
12/06
10:39
12/06/16
10:39
Conference/Events
Air Methods management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

SSNLF

Samsung

, AAPL

Apple

$109.11

-0.79 (-0.72%)

10:39
12/06/16
12/06
10:39
12/06/16
10:39
Periodicals
SCOTUS sides with Samsung in smartphone battle with Apple, Reuters reports »

The U.S. Supreme Court…

SSNLF

Samsung

AAPL

Apple

$109.11

-0.79 (-0.72%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

  • 08

    Dec

  • 13

    Mar

TASR

TASER

$28.08

0.16 (0.57%)

10:38
12/06/16
12/06
10:38
12/06/16
10:38
Conference/Events
TASER management to meet with Craig Hallum »

Meeting to be held in Los…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Dec

  • 07

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.